These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 36828507)

  • 21. Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States.
    Schrag SJ; Verani JR; Dixon BE; Page JM; Butterfield KA; Gaglani M; Vazquez-Benitez G; Zerbo O; Natarajan K; Ong TC; Lazariu V; Rao S; Beaver R; Ellington SR; Klein NP; Irving SA; Grannis SJ; Kiduko S; Barron MA; Midturi J; Dickerson M; Lewis N; Stockwell MS; Stenehjem E; Fadel WF; Link-Gelles R; Murthy K; Goddard K; Grisel N; Valvi NR; Fireman B; Arndorfer J; Konatham D; Ball S; Thompson MG; Naleway AL
    JAMA Netw Open; 2022 Sep; 5(9):e2233273. PubMed ID: 36156146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.
    Canaday DH; Oyebanji OA; White EM; Bosch J; Nugent C; Vishnepolskiy I; Abul Y; Didion EM; Paxitzis A; Sundheimer N; Ragavapuram V; Wilk D; Keresztesy D; Cao Y; St Denis K; McConeghy KW; McDonald LC; Jernigan JA; Mylonakis E; Wilson BM; King CL; Balazs AB; Gravenstein S
    MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(4):100-106. PubMed ID: 36701254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of Heterologous Coronavirus Disease 2019 (COVID-19) Vaccine Booster Dosing in Brazilian Healthcare Workers, 2021.
    Marra AR; Miraglia JL; Malheiros DT; Guozhang Y; Teich VD; da Silva Victor E; Rebello Pinho JR; Cypriano A; Vieira LW; Polonio M; Ornelas RH; de Oliveira SM; Borges Junior FA; Oler SCC; Schettino GPP; de Oliveira KG; Ferraz Santana RA; de Mello Malta F; Amgarten D; Boechat AL; Trecenti NMZ; Kobayashi T; Salinas JL; Edmond MB; Rizzo LV
    Clin Infect Dis; 2023 Feb; 76(3):e360-e366. PubMed ID: 35639918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of BNT162b2 Vaccination against SARS-CoV-2 Omicron Variant and Attitudes toward a COVID-19 Booster Dose among Healthy Thai Adolescents.
    Assavavongwaikit P; Chantasrisawad N; Himananto O; Phasomsap C; Klawaja P; Cartledge S; Nadsasarn R; Jupimai T; Kawichai S; Anugulruengkitt S; Puthanakit T; On Behalf Of The Study Team
    Vaccines (Basel); 2022 Jul; 10(7):. PubMed ID: 35891264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-Effectiveness of COVID-19 Sequential Vaccination Strategies in Inactivated Vaccinated Individuals in China.
    Fu Y; Zhao J; Wei X; Han P; Yang L; Ren T; Zhan S; Li L
    Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relative effectiveness of booster vs. 2-dose mRNA Covid-19 vaccination in the Veterans Health Administration: Self-controlled risk interval analysis.
    Korves C; Izurieta HS; Smith J; Zwain GM; Powell EI; Balajee A; Ryder KM; Young-Xu Y
    Vaccine; 2022 Aug; 40(33):4742-4747. PubMed ID: 35773122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12-17 years in Singapore: a national cohort study.
    Chiew CJ; Premikha M; Chong CY; Wei WE; Ong B; Lye DC; Heng D; Lee VJ; Tan KB
    Lancet Infect Dis; 2023 Feb; 23(2):177-182. PubMed ID: 36182678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need?
    Sritipsukho P; Khawcharoenporn T; Siribumrungwong B; Damronglerd P; Suwantarat N; Satdhabudha A; Chaiyakulsil C; Sinlapamongkolkul P; Tangsathapornpong A; Bunjoungmanee P; Nanthapisal S; Tanprasertkul C; Sritipsukho N; Mingmalairak C; Apisarnthanarak A; Tantiyavarong P
    Emerg Microbes Infect; 2023 Dec; 12(1):2174779. PubMed ID: 36715323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine.
    Chansaenroj J; Suntronwong N; Kanokudom S; Assawakosri S; Yorsaeng R; Vichaiwattana P; Klinfueng S; Wongsrisang L; Srimuan D; Thatsanatorn T; Thongmee T; Auphimai C; Nilyanimit P; Wanlapakorn N; Sudhinaraset N; Poovorawan Y
    Vaccines (Basel); 2022 Jul; 10(7):. PubMed ID: 35891235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prioritization of the Target Population for Coronavirus Disease 2019 (COVID-19) Vaccination Program in Thailand.
    Suphanchaimat R; Tuangratananon T; Rajatanavin N; Phaiyarom M; Jaruwanno W; Uansri S
    Int J Environ Res Public Health; 2021 Oct; 18(20):. PubMed ID: 34682548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimation of Vaccine Effectiveness of CoronaVac and BNT162b2 Against Severe Outcomes Over Time Among Patients With SARS-CoV-2 Omicron.
    Wei Y; Jia KM; Zhao S; Hung CT; Mok CKP; Poon PKM; Man Leung EY; Wang MH; Yam CHK; Chow TY; Guo Z; Yeoh EK; Chong KC
    JAMA Netw Open; 2023 Feb; 6(2):e2254777. PubMed ID: 36735253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The COVID-19 Humoral Immunological Status Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from a Booster Shot with the Pfizer Vaccine.
    Farias JP; da Silva PS; Fogaça MMC; Santana IVR; Luiz WB; Birbrair A; Amorim JH
    J Virol; 2022 Apr; 96(8):e0017722. PubMed ID: 35389263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Public health impact of booster vaccination against COVID-19 in the UK during Delta variant dominance in autumn 2021.
    Mendes D; Chapman R; Gal P; Atwell J; Nguyen JL; Hamson L; Di Fusco M; Czudek C; Yang J
    J Med Econ; 2022; 25(1):1039-1050. PubMed ID: 36097853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
    Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
    Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of mRNA Vaccine Booster against SARS-CoV-2 Infection and COVID-19 in the Adult Population during the First Three Months of the Omicron Wave in Sicily.
    Vella G; Genovese D; Belluzzo M; Mazzeo L; Pisciotta V; Amodio E
    Healthcare (Basel); 2023 Jan; 11(3):. PubMed ID: 36766880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Forecasted Trends of the New COVID-19 Epidemic Due to the Omicron Variant in Thailand, 2022.
    Suphanchaimat R; Teekasap P; Nittayasoot N; Phaiyarom M; Cetthakrikul N
    Vaccines (Basel); 2022 Jun; 10(7):. PubMed ID: 35891188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022.
    Link-Gelles R; Levy ME; Gaglani M; Irving SA; Stockwell M; Dascomb K; DeSilva MB; Reese SE; Liao IC; Ong TC; Grannis SJ; McEvoy C; Patel P; Klein NP; Hartmann E; Stenehjem E; Natarajan K; Naleway AL; Murthy K; Rao S; Dixon BE; Kharbanda AB; Akinseye A; Dickerson M; Lewis N; Grisel N; Han J; Barron MA; Fadel WF; Dunne MM; Goddard K; Arndorfer J; Konatham D; Valvi NR; Currey JC; Fireman B; Raiyani C; Zerbo O; Sloan-Aagard C; Ball SW; Thompson MG; Tenforde MW
    MMWR Morb Mortal Wkly Rep; 2022 Jul; 71(29):931-939. PubMed ID: 35862287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study.
    Fong CH; Zhang X; Chen LL; Poon RW; Chan BP; Zhao Y; Wong CK; Chan KH; Yuen KY; Hung IF; Yuen JKY; To KK
    EBioMedicine; 2023 Feb; 88():104446. PubMed ID: 36706582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Boosters and time from the last anti-COVID-19 vaccine dose: lead public health choices by real-time epidemiological assessment.
    Russo AG; Murtas R; Tunesi S; Decarli A; Bergamaschi W
    Epidemiol Prev; 2022; 46(1-2):34-46. PubMed ID: 35354266
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.
    Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y
    JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.